Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
Phase 3
Terminated
- Conditions
- Pulmonary Arterial Hypertension
- Registration Number
- NCT05557942
- Lead Sponsor
- Aerovate Therapeutics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Terminated
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Key Inclusion Criteria:<br><br>To be eligible, a participant is required to be or have:<br><br> - Consented to participate in the LTE and has successfully completed the<br> placebo-controlled 24-week Study AV-101-002.<br><br>Key Exclusion Criteria:<br><br>Subjects meeting any of the following criteria:<br><br> - The Investigator believes that it would not be in the best interest of the subject<br> to be included in the LTE e.g., for clinical or social reasons.<br><br> - Subjects who were not compliant with study medication in AV-101-002 as assessed by<br> the Investigator.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and tolerability of AV-101
- Secondary Outcome Measures
Name Time Method